Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEAL: Zibotentan and Dapagliflozin in Cirrhosis With Portal Hypertension
NCT05516498Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of zibotentan in Liver cirrhosis (LC), Portal Hypertension (PH), sponsored by AstraZeneca. Started Oct 2022; status: terminated.
02
Drugs
zibotentan
03
Conditions
Liver cirrhosis (LC)Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT05516498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516498.